IN THE NEWS
-
INTEGRAGEN ACHIEVES CE MARKING FOR MERCURY™, A CLOUD-BASED SOFTWARE APPLICATION FOR INTERPRETING MOLECULAR DATA FROM CANCER PATIENTS' TUMORS
IntegraGen announces the CE marking of its cloud-hosted online software application, MERCURY™ for tumor molecular data interpretation. This CE marking strengthens IntegraGen's ability to sell MERCURY... Read More
-
INTEGRAGEN UPDATE - ALWAYS OPEN FOR YOUR PROJECTS
IntegraGen follows government recommendations and precautionary measures related to the COVID-19 crisis. As a leading provider of genomic services, we are committed to... Read More
-
INTEGRAGEN - ANNUAL RESULTS 2019
Sales growth (+201TP3Q), positive EBITDA in the second half and close to breakeven for the full year IntegraGen today announced its financial results for the year ended... Read More
LATEST NEWS
-
INTEGRAGEN RENEWS PARTNERSHIP AGREEMENT WITH INSTITUT PASTEUR FOR HIGH THROUGHPUT SEQUENCING IN MICROBIOLOGY
IntegraGen today announced the renewal, until December 2021, of its partnership agreement with the Institut Pasteur... Read More
-
INTEGRAGEN PRESENTS RESULTS OF A STUDY EXTENDING THE IMPACT OF MIR-31 EXPRESSION MEASUREMENT TO STAGE III COLON CANCER PATIENTS AT ESMO 2018
Analysis of samples from the PETACC 8 phase III clinical trial shows that the... Read More
-
INTEGRAGEN NOMINATED FOR THE GALIEN MEDSTARTUP AWARD 2018
IntegraGen has been nominated for the Prix Galien MedStartup 2018, a joint initiative between the... Read More
-
GOPATH LABORATORIES ANNOUNCE THE LAUNCH OF THE MIR-31NOW TEST
GoPath Laboratories today announced the launch of a new proprietary test, miR31nowTM, to coincide with... Read More
